Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemagglutinin Protein of Influenza B-Yamagata Lineage Virus (HA)
- Target
- HA
- Molecular classification
- Glycoprotein, Viral protein, Surface glycoprotein
01
Overview
The hemagglutinin (HA) protein of the Influenza B-Yamagata lineage is a surface glycoprotein essential for viral entry into host respiratory epithelial cells. It binds to sialic acid receptors on host cells, initiating endocytosis and subsequent membrane fusion. HA is a major antigenic determinant, making it a primary target for neutralizing antibodies and a key component of influenza vaccines. The Yamagata lineage is antigenically distinct from the Victoria lineage, and its circulation has been significantly impacted by COVID-19 pandemic measures.
- Other names
- Influenza B Yamagata HemagglutininB/Yamagata HA
02
Mechanism of action
HA mediates viral entry into host cells by binding to sialic acid receptors and facilitating membrane fusion. Antibodies targeting HA can neutralize the virus by blocking these functions.
03
Biological functions
Receptor bindingMembrane fusionViral entryAntigen presentation
04
Disease associations
InfectionInfluenza
05
Safety considerations
Antigenic drift leading to vaccine mismatchPotential for antibody-dependent enhancement (ADE), though less common in influenza B
06
Interacting drugs
NA inhibitors (e.g., Oseltamivir, Zanamivir) - indirectly, by preventing viral release
1 more in the full profile.
07
Biomarkers
HA sequence variations (for monitoring antigenic drift)Antibody titers against HA (for assessing immunity)
Beyond the preview
Go deeper on Hemagglutinin Protein of Influenza B-Yamagata Lineage Virus (HA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemagglutinin Protein of Influenza B-Yamagata Lineage Virus (HA).